SCHEMBL17366374

SCHEMBL17366374

CCOc1ccc(N(c2ccc(/C=N/N(c3ccccc3)c3ccccc3)cc2)c2ccc(/C=N/N(c3ccccc3)c3ccccc3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.52
RELA Q04206 2/20 0.51
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
TAAR1 Q96RJ0 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 4/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
POLB P06746 1/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX12 P18054 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
KDM4E B2RXH2 1/20 0.44
AHR P35869 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LTA4H P09960 1/20 0.44
G6PC1 P35575 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8576277 0.96 GAA (0.56) GAARELAMEN1KMT2ATAAR1
SCHEMBL8576278 0.96 GAA (0.56) GAARELAMEN1KMT2ATAAR1
SCHEMBL10105968 0.90 MEN1 (0.44) GAARELAMEN1KMT2ATAAR1
SCHEMBL13986164 0.86 LMNA (0.43) GAAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL14342245 0.85 G6PC1 (0.55) GAARELAMEN1KMT2ASMN1; SMN2
SCHEMBL13655507 0.85 G6PC1 (0.55) GAARELAMEN1KMT2ASMN1; SMN2
SCHEMBL332093 0.84 CYP1A2 (0.53) GAAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL332094 0.84 CYP1A2 (0.53) GAAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL17366379 0.84 RELA (0.54) GAARELAMEN1KMT2ATAAR1
SCHEMBL14087532 0.83 NPC1 (0.55) GAAMEN1KMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2960229-B1 HYDRAZONE DERIVATIVE OF TRIPHENYLAMINE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER KYOCERA DOCUMENT SOLUTIONS INC (JP) 2017-02-15 EP disclosed
US-9454091-B2 Hydrazone derivative of triphenylamine and electrophotographic photosensitive member KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2016-09-27 US disclosed
US-9454091-B2 Hydrazone derivative of triphenylamine and electrophotographic photosensitive member KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2016-09-27 US disclosed
US-20150378269-A1 HYDRAZONE DERIVATIVE OF TRIPHENYLAMINE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2015-12-31 US disclosed
US-20150378269-A1 HYDRAZONE DERIVATIVE OF TRIPHENYLAMINE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2015-12-31 US disclosed
EP-2960229-A1 HYDRAZONE DERIVATIVE OF TRIPHENYLAMINE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER Kyocera Document Solutions Inc. (JP) 2015-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150378269-A1 HYDRAZONE DERIVATIVE OF TRIPHENYLAMINE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER NAT1, GSTA1, PKN1 GAA 3854/4885RELA 2887/4885MEN1 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.